ALHCALHCHealthcare · Healthcare Plans

ALHC Stock Forecast: Alignment Healthcare, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$15
−1.95% on the day

The 14 Wall Street analysts covering Alignment Healthcare, Inc. hold a median 12-month price target of $25 — +71.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 70 of 100 as at 1 Aug 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$3.1B
Ticker Nerd rank
70 / 100
Median analyst target
$25
Analysts covering
14
Total return, dividends reinvested
1W
−22.0%
1M
−38.8%
YTD
−26.3%
1Y
+12.3%
From 52W high
−40.7%
From 52W low
+9.5%
$13
$25
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ALHC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Alignment Healthcare, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
70 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
79
Accruals
73
Volatility
71
Momentum
63
Quality
63
Revisions
61
Value
57
Issuance
41
Size
30

Growth (79): Sales and profits are climbing, and climbing faster than before.

Issuance (41): The company has been issuing shares or taking on financing, diluting existing holders.

Size (30): Larger than most of the companies we track — more scrutinised, less often mispriced.

The rank is the raw material. Whether the rules would actually own Alignment Healthcare, Inc. — and when they’d sell — is the membership.

Wall Street

ALHC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALHC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$15$20$25$30Oct 25Jan 26Apr 26Jul 26ALHCHigh $30Median $25Low $16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says14 analysts
12 Buy2 Hold0 Sell
Low $16Median $25High $30

The green dot is the last close — the median target sits +71.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
26 May 2026BarclaysMaintainsEqual-Weight$19$16
26 May 2026BarclaysMaintainsEqual-Weight
1 May 2026BarclaysMaintainsEqual-Weight
1 May 2026UBSMaintainsNeutral
5 Feb 2026JP MorganMaintainsOverweight
16 Jan 2026TD CowenMaintainsBuy
14 Jan 2026UBSMaintainsNeutral
6 Jan 2026Piper SandlerMaintainsOverweight
17 Dec 2025JP MorganMaintainsOverweight
24 Nov 2025JP MorganUpgradeOverweight
5 Nov 2025JP MorganMaintainsNeutral
3 Nov 2025BarclaysMaintainsEqual-Weight
31 Oct 2025UBSMaintainsNeutral
14 Oct 2025Goldman SachsInitiatesBuy
25 Aug 2025KeybancUpgradeOverweight
31 July 2025BarclaysUpgradeEqual-Weight
2 May 2025UBSMaintainsNeutral
15 Apr 2025BairdMaintainsOutperform
8 Apr 2025StifelMaintainsBuy
6 Mar 2025JP MorganMaintainsNeutral

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

ALHC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+8.6%
Analysts raising
0
Analysts cutting
0
Fundamentals

Alignment Healthcare, Inc. (ALHC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
78.2×

Cheaper than 9% of US stocks

Price / sales
0.7×

Cheaper than 78% of US stocks

Price / book
11.6×

Cheaper than 9% of US stocks

EV / EBITDA
31.0×

Cheaper than 9% of US stocks

Growth & margins
Revenue growth (YoY)
31.6%

Higher than 80% of US stocks

Earnings growth (YoY)
133.4%

Higher than 89% of US stocks

Gross margin
13.5%

Higher than 14% of US stocks

Operating margin
3.2%

Higher than 54% of US stocks

Net margin
0.9%

Higher than 49% of US stocks

Returns & dividend
Return on equity
20.0%

Higher than 82% of US stocks

Return on assets
3.1%

Higher than 66% of US stocks

Dividend yield

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ALHC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealthcare Plans
CompanyMarket capTKN rank
ALHCAlignment Healthcare, Inc.$3.1B
70
PGNYProgyny, Inc.$2.4B
99
CLOVClover Health Investments Corp.$2.2B
59
OSCROscar Health, Inc.$9.3B
54
MOHMolina Healthcare, Inc.$10.1B
30
CNCCentene Corp.$30.6B
89
HUMHumana, Inc.$43.8B
44
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALHC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest ALHC news & analysis

Securities Fraud Investigation Into Alignment Healthcare, Inc. (NASDAQ: ALHC) Following Whistleblower Lawsuit Of Financial Manipulation Continues

GlobeNewsWire · 3 Aug 2026negative

Glancy Prongay Wolke & Rotter LLP is continuing a securities fraud investigation into Alignment Healthcare for possible violations of federal securities laws, following a whistleblower lawsuit alleging financial manipulation and a 16% stock price drop on July 8, 2026.

Why it matters — ALHC watchers would care because the ongoing investigation and whistleblower allegations could expose the company to legal and reputational risk.

Down 37.6% in 4 Weeks, Here's Why Alignment Healthcare (ALHC) Looks Ripe for a Turnaround

Zacks Investment Research · 3 Aug 2026positive

Alignment Healthcare (ALHC) stock has fallen 37.6% over the past four weeks and is now technically oversold, according to the report. Wall Street analysts show strong agreement in revising earnings estimates higher, which the source suggests indicates a potential near-term trend reversal.

Why it matters — An ALHC watcher would care because the combination of an oversold technical position and upward analyst estimate revisions points to a possible turnaround in the stock in the near term.

Kaplan Fox Advises Investors of Alignment Healthcare, Inc. (NASDAQ: ALHC) of an Investigation into Possible Securities Law Violations

GlobeNewsWire · 3 Aug 2026negative

Kaplan Fox & Kilsheimer LLP announced it is investigating potential securities violations against Alignment Healthcare, Inc. and is inviting investors who have suffered losses to contact the firm.

Why it matters — An investigation into possible securities law violations could signal legal or regulatory risk for Alignment Healthcare that investors may want to monitor.

Alignment Healthcare, Inc. (ALHC) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Ongoing Securities Fraud Investigation

GlobeNewsWire · 3 Aug 2026negative

Law Offices of Howard G. Smith announced an ongoing securities fraud investigation on behalf of Alignment Healthcare, Inc. (ALHC) shareholders who lost money. The firm is inviting affected shareholders to contact them regarding the matter.

Why it matters — An active securities fraud investigation introduces legal and reputational risk for ALHC and is directly relevant to shareholders monitoring the company.

Kaplan Fox is Investigating Alignment Healthcare, Inc. (ALHC) and Encourages Investors Who Suffered Losses to Contact the Firm

Newsfile Corp · 3 Aug 2026negative

Kaplan Fox & Kilsheimer LLP announced it is investigating potential securities violations against Alignment Healthcare, Inc. (NASDAQ: ALHC). The firm is encouraging investors who suffered losses or have relevant information to contact them.

Why it matters — ALHC watchers would care because the company is now the subject of a securities investigation tied to potential violations and investor losses.

FAQ

Frequently asked questions about ALHC stock

What is the ALHC stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Alignment Healthcare, Inc. have a median 12-month price target of $25, with estimates ranging from $16 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALHC stock a buy right now?

Of the 14 analysts covering Alignment Healthcare, Inc., 12 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alignment Healthcare, Inc. 70 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALHC?

As at 1 Aug 2026, Alignment Healthcare, Inc. ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (79 of 100).

Will ALHC stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +71.7% from the last close, and Ticker Nerd's factor model ranks Alignment Healthcare, Inc. 70 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALHC stock forecast for 2030?

No analyst covering Alignment Healthcare, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALHC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $30 over the next 12 months.

How has ALHC stock performed over the past year?

Alignment Healthcare, Inc. returned +12.3% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Alignment Healthcare, Inc. do?

Alignment Healthcare, Inc. is a health insurance company specializing in Medicare Advantage coverage for older adults in the United States.

What is the latest news on ALHC?

The most recent item we track (GlobeNewsWire, 3 Aug 2026): "Securities Fraud Investigation Into Alignment Healthcare, Inc. (NASDAQ: ALHC) Following Whistleblower Lawsuit Of Financial Manipulation Continues". Glancy Prongay Wolke & Rotter LLP is continuing a securities fraud investigation into Alignment Healthcare for possible violations of federal securities laws, following a whistleblower lawsuit alleging financial manipulation and a 16% stock price drop on July 8, 2026.

Company

About Alignment Healthcare, Inc.

Alignment Healthcare, Inc. is a health insurance company specializing in Medicare Advantage coverage for older adults in the United States. The firm operates a consumer-centric healthcare platform that integrates plan administration, clinical services, and technology to deliver a more coordinated care experience for seniors. Its primary function is to design and manage Medicare Advantage plans that typically bundle medical, hospital, prescription drug, and supplemental benefits such as dental, vision, and hearing into a single managed-care offering. Alignment Healthcare focuses on senior-first care management, using its proprietary AVA technology platform and a concierge-style care team to support clinical coordination, identify health risks, and help manage chronic conditions. The company works closely with physicians, hospitals, and other providers to organize care delivery, aiming to improve outcomes while maintaining cost-effective coverage for Medicare-eligible members. Headquartered in Orange, California and operating as a single Medicare Advantage segment, Alignment Healthcare plays a specialized role in the U.S. healthcare plans industry, serving seniors who want integrated insurance coverage and navigation support within the Medicare Advantage market.

CEO Mr. John E. Kao · 1,849 employees · United States · https://www.alignmenthealth.com